The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

According to J&J, Spravato is an N-methyl-D-aspartate (NMDA) receptor antagonist that appears ... that the treatments work,” Merrill said. “Ketamine is a safe medication when used under ...

Medicare does not typically cover ketamine infusions for mental health conditions. However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

The US FDA has approved the first of its kind ketamine-based nasal spray which ... the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first ... The drug is the first ketamine-based medicine approved to treat depression. Ketamine has long been ...

Heaps of ketamine, MDMA and illegal weed were seized by authorities as they busted a drug lab in Queens and arrested the ringleader of the dangerous narcotics operation, prosecutors said Friday.

Johnson & Johnson's Spravato therapy for treatment-resistant ... an intranasal formulation of racemic ketamine.